Small molecule · Antagonist of P2Y12 receptor (P2RY12) · developed by Viatris Innovation GmbH
Selatogrel is a reversible P2Y12 receptor antagonist given subcutaneously. It blocks the P2Y12 receptor on platelets, inhibiting platelet activation and aggregation. It is studied in stable coronary artery disease and acute myocardial infarction.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03487445 | Phase 2 | Acute Myocardial Infarction | Completed | VTRS |
| NCT03384966 | Phase 2 | Stable Coronary Artery Disease | Completed | VTRS |
| NCT03814200 | Phase 1 | Healthy Subject | Completed | VTRS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myocardial InfarctionHealthy SubjectStable Coronary Artery Disease
Updated Nov 1, 2026. Something wrong or missing? Report it on the VTRS page.
See VTRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VTRS catalysts and pipeline →